THCA inhibited cell proliferation in various prostate carcinoma cell (PCC) lines, including (i) androgen-receptor positive cells (LNCaP and 22RV1) with IC50 of 22.1 ± 2 μM or 17.1 ± 1 μM in the presence or absence of serum, respectively, (ii) androgen-receptor negative cells (DU-145 and PC-3) with IC50 of >25 μM (21.9% inhibition) or 21.6 ± 2 μM in the presence or absence of serum, respectively [62]. Here, AR is linked to prostate carcinoma.